Spago Nanomedical Strengthens Tumorad® by Institution of Scientific Advisory Board

Spago Nanomedical AB (publ) at the moment introduced the institution of a Scientific Advisory Board (SAB) comprised of scientific and scientific leaders in oncology and nuclear medication. The SAB will present assist and steerage within the scientific growth of the radiopharmaceutical program Tumorad with the candidate drug 177Lu-SN201. On the outset the SAB consists of three distinguished members; Professor Sten Nilsson, Professor Kristian Pietras and Dr. Austin Smith.

We’re very happy to assign Austin, Kristian and Sten to Spago Nanomedical’s Scientific Advisory Board for Tumorad. Collectively they supply a wealth of data and expertise within the growth of novel radionucleotide therapies for most cancers. Their collective experience might be instrumental as we proceed Tumorad by means of the scientific and regulatory growth section, which not too long ago commenced by the scientific trial utility for a section I/IIa research in sufferers with superior most cancers,” stated CEO Mats Hansen.

The SAB will assist information the longer term path of Tumorad’s scientific growth. Reviewing ongoing knowledge and contributing medical and scientific information the Advisory Board could have an vital function in making certain the Tumorad program can meet its goals of bringing a brand new and priceless therapy choice to probably the most applicable sufferers. Further members could also be added to the Advisory Board as this system progresses.

The present members of the Tumorad SAB are:

Professor Sten Nilsson

Sten is a specialist and professor emeritus in oncology on the Division of Oncology-Pathology, Karolinska, in addition to a specialist in nuclear medication. Sten was liable for the research design and led the early scientific program Xofigo (beforehand Alpharadin). Sten was beforehand the chairman of the Swedish Oncology Affiliation (SOF) and the Swedish Affiliation for Nuclear Medication (SFNM) and member of EANM’s Radionuclide Remedy Job Drive. He has printed over 200 scientific articles.

Professor Kristian Pietras

Kristian is a professor in Molecular Medication at Lund College, specializing in translational most cancers analysis as a hub between fundamental science, scientific science and the pharmaceutical trade. Kristian has made vital contributions in defining tumors as speaking organs comprising a number of cell varieties that collectively maintain most cancers development. Kristian has been a member and chairman of the Younger Academy of Sweden, and is an elected member of the Royal Physiographic Society. He has printed over 100 analysis articles and patents.

Dr. Austin Smith

Austin is skilled and certified in Medical Oncology and Pharmaceutical Medication. Austin is a graduate of the Royal School of Surgeons, Eire and has a stable background in all facets of Oncology and Malignant Hematology, together with Regulatory Science expertise throughout Europe, the US and Asia-Pacific areas, performing in senior and government positions in biopharma firms. Austin can be a member of the Professional Group for Oncology, representing the College of Pharmaceutical Medication within the UK.


Leave a Reply

Your email address will not be published. Required fields are marked *